NCT00812383CompletedPhase 2
Carotid With Bivalirudin Angioplasty
Medstar Health Research Institute2 sites in 1 country299 target enrollmentStarted: August 1, 2003Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 299
- Locations
- 2
- Primary Endpoint
- To evaluate clinical success (<50% residual stenosis at all treatment sites without death, myocardial infarction, stroke or major bleed)
Study Overview
Brief Summary
Single center randomized clinical trial, to evaluate the safety and efficacy of carotid artery stenting using the RX ACCULINK™ Carotid Stent System with RX ACCUNET™ Embolic Protection System or PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System using Angiomax (bivalirudin)versus heparin as the anticoagulant for treatment of occlusive carotid artery disease in low and high risk patient cohorts.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •The patient must be at least 18 years of age.
- •The patient must have a significant diameter reduction of the extracranial or intracranial internal or common carotid artery, defined as ≥50% stenosis for symptomatic patients or ≥80% stenosis for asymptomatic patients determined by carotid duplex ultrasound scan and/or carotid angiography.
- •Female patients with child bearing potential must have a negative pregnancy test.
- •The patient and the patient's physician must agree to have the patient return for a 30-day and one-year clinical and ultrasound imaging follow-up evaluations as indicated in the protocol.
- •Reference vessel diameter ≥ 3.5 mm - ≤ 9.0 mm diameter.
Exclusion Criteria
- •The patient has had a recent (<4 weeks) disabling stroke or dementia with major neurologic deficit (stroke scales: Barthel <60, NIH >15, or Rankin >3) at pre-procedure neuro exam.
- •The patient has had within four weeks of the treatment procedure an intracranial hemorrhage, hemorrhage stroke, major stroke, or any stroke with mass effect demonstrated on MRI or CT.
- •The patient has a known allergy to heparin, bivalirudin, aspirin or to anti-platelet agents that prevents taking aspirin plus ticlopidine or aspirin plus clopidogrel.
- •The patient has received fractionated or unfractionated heparin within 8 hours prior to the procedure.
- •The patient has a history of prior life-threatening radiocontrast reaction that cannot be pre-treated.
- •The patient has a history of bleeding diathesis or coagulopathy within 3 months.
- •The patient is currently participating in another study protocol that may influence either procedure results or follow-up evaluations.
- •Plasma/serum creatinine > 3.0 mg/dl at time of intervention.
- •Hemodynamic instability at the time of intervention.
- •Previous stent placement in the ipsilateral carotid distribution.
- •Angiographic Exclusion Criteria
- •The patient has an intracranial tumor, or cerebral arterio-venous malformation(s) > 5mm, aneurysms or severe intracranial stenosis distal to target lesion.
- •The patient has inaccessible intracranial arterial stenosis greater in severity than the extracranial internal carotid artery lesion.
- •There is angiographic evidence of significant intra-luminal thrombus burden with presumed increased risk of plaque fragmentation and consequent distal embolization.
- •There is total occlusion of the ipsilateral carotid artery treatment site with TIMI 0 flow characteristics.
- •The reference segment diameter (internal carotid artery segment cephalad to the lesion) is less than 3 millimeters by operator visual estimate.
- •The patient has peripheral vascular, supra-aortic or internal carotid artery tortuosity precluding use of catheter-based techniques required for successful CSSA
Outcomes
Primary Outcomes
To evaluate clinical success (<50% residual stenosis at all treatment sites without death, myocardial infarction, stroke or major bleed)
Time Frame: 30 days
Secondary Outcomes
- To assess stent patency , and occurence of death or recurrent neurological events(12 months)
- To assess for complications including death, myocardial infarction, major or minor stroke, major or minor bleeding, and vascular complications.(In hospital and 30 days)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 4
A Single Center of Carotid Stenting With Distal Protection for the Treatment of Obstructive Carotid Artery DiseaseHeart DiseaseBrain Vascular AccidentCarotid Artery DiseaseCarotid StenosisNCT00178672The University of Texas Health Science Center, Houston69
Recruiting
Not Applicable
Carotid Artery Stent Implantation in the Treatment of Vulnerable PlaqueCarotid Artery PlaqueCarotid StenosisStent EmbolisationNCT05524207Beijing Tsinghua Chang Gung Hospital100
Completed
Not Applicable
A Randomized Trial of Carotid Artery Stenting With and Without Cerebral ProtectionCarotid Artery StenosisNCT00177346University of Pittsburgh52
Recruiting
Not Applicable
Timing Carotid Stent Clinical Study for the Treatment of Carotid Artery Stenosis（Timing Trial）Carotid Artery DiseasesIschemic StrokeStrokeCarotid Artery StenosisNCT05574972Suzhou Zenith Vascular Scitech Co., Ltd.178
Unknown
Not Applicable
A Prospective, Non-Randomized, Evaluation of Low-Risk Patients Undergoing Carotid Stenting With ANgiomax (Bivalirudin)Carotid StenosisNCT01273350SPSI d.b.a Capital Cardiovascular Associates154